Literature DB >> 25101721

Cancer centers zero in on exceptional responders.

Cormac Sheridan.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 25101721     DOI: 10.1038/nbt0814-703

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  Genome sequencing identifies a basis for everolimus sensitivity.

Authors:  Gopa Iyer; Aphrothiti J Hanrahan; Matthew I Milowsky; Hikmat Al-Ahmadie; Sasinya N Scott; Manickam Janakiraman; Mono Pirun; Chris Sander; Nicholas D Socci; Irina Ostrovnaya; Agnes Viale; Adriana Heguy; Luke Peng; Timothy A Chan; Bernard Bochner; Dean F Bajorin; Michael F Berger; Barry S Taylor; David B Solit
Journal:  Science       Date:  2012-08-23       Impact factor: 47.728

2.  Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Authors:  Nikhil Wagle; Brian C Grabiner; Eliezer M Van Allen; Eran Hodis; Susanna Jacobus; Jeffrey G Supko; Michelle Stewart; Toni K Choueiri; Leena Gandhi; James M Cleary; Aymen A Elfiky; Mary Ellen Taplin; Edward C Stack; Sabina Signoretti; Massimo Loda; Geoffrey I Shapiro; David M Sabatini; Eric S Lander; Stacey B Gabriel; Philip W Kantoff; Levi A Garraway; Jonathan E Rosenberg
Journal:  Cancer Discov       Date:  2014-03-13       Impact factor: 39.397

3.  A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma.

Authors:  Vivek Subbiah; Robert E Brown; Mary F McGuire; Jamie Buryanek; Filip Janku; Anas Younes; David Hong
Journal:  Oncotarget       Date:  2014-01-15

4.  Discovery and saturation analysis of cancer genes across 21 tumour types.

Authors:  Michael S Lawrence; Petar Stojanov; Craig H Mermel; James T Robinson; Levi A Garraway; Todd R Golub; Matthew Meyerson; Stacey B Gabriel; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2014-01-05       Impact factor: 49.962

  4 in total
  2 in total

1.  Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma.

Authors:  T Vu; W Gonsalves; S Kumar; A Dispenzieri; M Q Lacy; F Buadi; M A Gertz; S V Rajkumar
Journal:  Blood Cancer J       Date:  2015-10-23       Impact factor: 11.037

Review 2.  Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.

Authors:  Ping-Pin Zheng; Jin Li; Johan M Kros
Journal:  Med Res Rev       Date:  2017-09-01       Impact factor: 12.944

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.